Format

Send to

Choose Destination
Nutrients. 2018 Nov 3;10(11). pii: E1651. doi: 10.3390/nu10111651.

Resveratrol, Metabolic Syndrome, and Gut Microbiota.

Author information

1
Cardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA. amc315@case.edu.
2
INSERM U1048, Institute of Metabolic and Cardiovascular Diseases (I2MC) and University Paul Sabatier, 31432 Toulouse, France. christian.carpene@inserm.fr.
3
Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, 07122 Palma, Spain. josep.mercader@uib.es.
4
Balearic Islands Health Research Institute (IdISBa), 07122 Palma, Spain. josep.mercader@uib.es.

Abstract

Resveratrol is a polyphenol which has been shown to have beneficial effects on metabolic syndrome-related alterations in experimental animals, including glucose and lipid homeostasis improvement and a reduction in fat mass, blood pressure, low-grade inflammation, and oxidative stress. Clinical trials have been carried out to address its potential; however, results are still inconclusive. Even though resveratrol is partly metabolized by gut microbiota, the relevance of this "forgotten organ" had not been widely considered. However, in the past few years, data has emerged suggesting that the therapeutic potential of this compound may be due to its interaction with gut microbiota, reporting changes in bacterial composition associated with beneficial metabolic outcomes. Even though data is still scarce and for the most part observational, it is promising nevertheless, suggesting that resveratrol supplementation could be a useful tool for the treatment of metabolic syndrome and its associated conditions.

KEYWORDS:

gut microbiota; metabolic syndrome; resveratrol

PMID:
30400297
PMCID:
PMC6266067
DOI:
10.3390/nu10111651
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center